CORIN GROUP acquired by PERMIRA

Ardian acquired a majority stake in Inula from Vendis Capital and founder Dominique Baudoux. The founder and Vendis Capital retained reinvestment options, while the CEO and the management team reinvested significantly to increase their equity stake. The acquisition aimed to leverage Ardian's global footprint to accelerate Inula's expansion in the US, Italy, and Germany, and to pursue buy-and-build opportunities in the fragmented aromatherapy market.

The acquisition of Acteon by Dentressangle represents a major turning point in the medtech’s trajectory, moving toward an aggressive buy-and-build strategy. The strategic rationale for this transaction centers on an "industrial-consolidation" play, merging the group’s industry-leading technical operational depth in ultrasonic surgery with the sponsor’s extensive expertise in executing international build-up operations. This structural alignment provides the organization with the institutional capital and strategic guidance required to address the increasing demand for integrated dental technology suites

The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets. The strategic rationale for the transaction centers on the fusion of Paragon Medical’s niche leadership in orthopedic instrumentation with NN, Inc

PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally

Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board. Meanwhile, Bruno Duval, the company's founder, will retain a key role as a shareholder and become Chairman of the Supervisory Board. The goal of this transaction is to support Théradial's growth strategy, which aims to leverage its pharmaceutical establishment status, obtained two years ago, to expand its product portfolio

CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.

Fresenius Medical Care announced a definitive agreement to acquire all outstanding shares of NxStage Medical. The acquisition is strategically central to FMC's 2020 strategic initiative, positioning the combined entity as a global leader in home dialysis by integrating NxStage's System One platform into FMC's vertically integrated dialysis ecosystem. The transaction is expected to generate net cost synergies of approximately $80–100 million per annum before tax over three to five years, with integration costs of approximately $150 million over the first three years

This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership. The historical controlling shareholder and the incumbent management team are significantly reinvesting their proceeds to retain a robust equity position while continuing to lead day-to-day operations. Charterhouse utilizes its latest flagship investment vehicle to capitalize this partnership

EQT VII has entered into an agreement to acquire a 20% minority stake in Ottobock, as part of a strategic partnership aimed at supporting Ottobock's international growth ambitions, driving its strategic objectives, and potentially preparing the company for a future initial public offering (IPO) in the medium term. The investment by EQT comes at a time of significant transformation in the mobility technology market, driven by an aging population, increasing demand for rehabilitation solutions, and advancements in smart prosthetics

Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector. Rather than a simple portfolio addition, this move represents a calculated bet on the structural transition toward decentralized laboratory automation and precision pathology